Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 4/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 9/20 | 0.43 |
| ▸ | WEE1 | P30291 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.36 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553653 | 0.90 | PTK2 (0.47) | PTK2TNK2WEE1PAK4PKN1 | |
| SCHEMBL15785231 | 0.82 | TNK2 (0.46) | PTK2TNK2WEE1PAK4PKN1 | |
| SCHEMBL13553667 | 0.81 | PTK2 (0.47) | PTK2TNK2WEE1PAK4PKN1 | |
| SCHEMBL15036015 | 0.81 | PTK2 (0.48) | PTK2TNK2WEE1PAK4PKN1 | |
| SCHEMBL15785302 | 0.76 | TNK2 (0.51) | PTK2TNK2PAK4PKN1 | |
| SCHEMBL16309177 | 0.73 | PTK2 (0.43) | PTK2TNK2WEE1PAK4PKN1 | |
| SCHEMBL13553800 | 0.72 | PTK2 (0.46) | PTK2TNK2WEE1PAK4PKN1 | |
| SCHEMBL15035062 | 0.72 | MAP4K1 (0.48) | PTK2TNK2WEE1PAK4PKN1 | |
| SCHEMBL15041550 | 0.72 | PTK2 (0.51) | PTK2TNK2WEE1FLT4KDR | |
| SCHEMBL15281134 | 0.72 | WEE1 (0.49) | PTK2TNK2WEE1PAK4PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PTK2 12/4885TNK2 7/4885WEE1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.